Literature DB >> 4030989

Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.

J Cummings.   

Abstract

4'-Deoxydoxorubicin (4'-DOX) is a new and structurally similar analogue of the anti-cancer drug adriamycin (ADR). Based on known pathways of metabolism of ADR a high-performance liquid chromatographic method for the separation and identification of 4'-DOX and five possible metabolites was developed. Sensitivity for serum is 10 ng/ml for 4'-DOX and its alcoholic product 4'-deoxydoxorubicinol (4'-DOL) and 2 ng/ml for four of its aglycone products with coefficients of variation in k' of less than 5% throughout the day. An extraction step with better than 80% recovery of 4'-DOX and five reference metabolites from serum is described. Analysis of patient sera identified two metabolite peaks. These co-eluted with the reference metabolites of 4'-DOL and the 7-deoxyaglycone of 4'-DOX. Pharmacokinetics of the parent drug followed a two-compartment model. Both the metabolites were produced quickly and disappeared quickly.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030989     DOI: 10.1016/s0378-4347(00)84053-0

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.

Authors:  Jennifer A MacDiarmid; Nancy B Amaro-Mugridge; Jocelyn Madrid-Weiss; Ilya Sedliarou; Stefanie Wetzel; Kartini Kochar; Vatsala N Brahmbhatt; Leo Phillips; Scott T Pattison; Carlotta Petti; Bruce Stillman; Robert M Graham; Himanshu Brahmbhatt
Journal:  Nat Biotechnol       Date:  2009-06-28       Impact factor: 54.908

2.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.

Authors:  J Cummings; D J Kerr; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.

Authors:  J Cummings; G J Forrest; D Cunningham; N L Gilchrist; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug.

Authors:  J Cummings; C S McArdle
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

6.  Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.

Authors:  G Vlahovic; A M Ponce; Z Rabbani; F K Salahuddin; L Zgonjanin; I Spasojevic; Z Vujaskovic; M W Dewhirst
Journal:  Br J Cancer       Date:  2007-08-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.